Sustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosis

This publication has 15 references indexed in Scilit:

• Sustained Remission Off‐Therapy in a Case of Infantile ALK‐Positive Multisystem Histiocytosis Treated With Crizotinib
  Pediatric Blood & Cancer, 2025
• Multisystem ALK‐Positive Histiocytosis With DCTN1::ALK Fusion in an Adult, Responsive to Alectinib: Case Report and Literature Review
  Journal of Cutaneous Pathology, 2024
• Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium
  Blood Neoplasia, 2024
• Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms
  British Journal of Haematology, 2023
• Lorlatinib use in an infant with thalamic ALK‐positive histiocytosis
  Pediatric Blood & Cancer, 2023
• The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
  Leukemia, 2022
• ALK‐rearranged histiocytosis: Report of two cases with involvement of the central nervous system
  Neuropathology and Applied Neurobiology, 2021
• Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms
  Nature Medicine, 2019
• ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion
  Laboratory Investigation, 2019
• ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy
  Blood, 2008